The Global Postpartum Depression Drug Market Growth Accelerated By Increase In Prevalence Of Postpartum Depression
Postpartum depression is a type of depression that affects women after childbirth. It manifests through symptoms such as feelings of worthlessness, sadness, and inability to bond with the baby. The drugs used for treating postpartum depression help in combating these symptoms by altering the levels of mood-regulating neurotransmitters like serotonin and norepinephrine in the brain. The global postpartum depression drug market is estimated to be valued at US$ 6.65 Bn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of postpartum depression among new mothers is one of the major trends driving the growth of the postpartum depression drug market. According to the World Health Organization (WHO), out of every 10 mothers worldwide, 1-2 mothers suffer from postpartum depression. The risk factors associated with postpartum depression include previous mental health issues, lack of social support, marital problems, and childcare stress. Thus, the rising awareness regarding these risk factors and diagnosis of postpartum depression is contributing to the growing demand for drugs to effectively treat the condition. Furthermore, key players in the market are focusing on developing new treatment options such as antidepressants, anti-anxiety drugs, and psychotherapy to reach a wider patient pool and accelerate the market growth over the forecast period.
Segment Analysis
The global postpartum depression drug market is dominated by selective serotonin reuptake inhibitors (SSRIs) sub-segment. SSRIs are the first line treatment prescribed for postpartum depression, as they are considered relatively safe for breastfeeding mothers and infants. Additionally, SSRIs do not cause dependency or withdrawal symptoms, unlike other antidepressants. The SSRI sub-segment accounted for over 50% market share in 2023.
Key Takeaways
Regional analysis
The Global Postpartum Depression Drug Market is expected to witness high growth in the Asia Pacific region. This region is estimated to grow at the fastest rate during the forecast period, owing to rising awareness about mental health issues and increasing number of initiatives by governments and nonprofit organizations to reduce stigma associated with postpartum depression. Countries like China, India, and Japan are dominating the Asia Pacific market.
Key players
Key players operating in the postpartum depression drug market are Sun Pharma, UCB Farchim SA, Yangtze River Pharmaceutical (Group) Co., Ltd., Livzon Pharmaceutical Group Inc., Nanjing Sanhome Pharmaceutical Co.,Ltd., PKU Healthcare Corp., Ltd., Qilu Pharmaceutical Co., Ltd., Jilin Huakang Pharmaceutical Co., Ltd., Sichuan Hengrui Pharmaceutical Co., Ltd., Shaixi Taiyuan Pharmaceutical Co., Ltd., Guangdong Guoyuan Sinopharm Co., Ltd., Suzhou Dawnrays Pharmaceutical Co., Ltd., Zhejiang Zhebei Pharmaceutical Co., Ltd., Nanjing Chang'ao Pharmaceutical Co., Ltd., Xinhua Pharmaceutical (Gaomi) Co., Ltd.. These companies are focused on expanding their product portfolios by developing new formulations and line extensions.
Get more insights on this topic: http://marketerefforts.weebly.com/home/the-postpartum-depression-drug-market-is-estimated-to-witness-high-growth-owing-to-the-growing-prevalence-of-postpartum-depression
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian